素和心力衰竭:还是蛋?
Nikolaos Theodorakis1,2, Maria Nikolaou3
1Department of Cardiology & Heart Failure Outpatient Clinic, Sismanogleio-Amalia Fleming General Hospital, 14, 25 Martiou Str., 15127, Melissia, Greece.
Heart failure reviews
|March 17, 2025
概括
莱普通过促进炎症和代谢功能障碍来启动心力衰竭与保存的喷射分数 (HFpEF). 在心力衰竭中,降低射出分数 (HFrEF),丁会使现有的心脏问题恶化,这凸显了每个HF亚型的独特治疗策略.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 代谢综合征是代谢综合征的一种.
背景情况:
- 瘦素是一种调节食欲和新陈代谢的激素,在心力衰竭 (HF) 中表现出复杂的双重作用.
- 它的功能在保持射出分数 (HFpEF) 的高频和减少射出分数 (HFrEF) 的高频之间有很大差异.
- 了解这些不同的角色对于开发有针对性的治疗策略至关重要.
研究的目的:
- 阐明素在HFpEF和HFrEF中的不同作用.
- 探索针对各种HF亚型的丁信号传递的潜在治疗影响.
- 强调需要基于HF病理生理学的个性化治疗方法.
主要方法:
- 审查和综合现有的关于叶丁参与心血管疾病的文献.
- 在HFpEF中分析瘦素的机械路径,包括炎症,代谢功能障碍和心脏重塑.
- 对瘦素作为HFpEF的主要驱动因素与HFrEF中次要加重因素的比较分析.
主要成果:
- 在HFpEF中,慢性高脂血症是关键的驱动因素,与肥胖和代谢功能障碍有关,促进炎症,动脉硬和腹功能障碍.
- 在HFrEF中,升高的瘦素是心脏功能障碍和炎症的结果,放大了不良的神经激素激活和重塑.
- 减肥和特定药物等干预措施通过减轻高血平素血症,在HFpEF中表现有前途.
结论:
- 丁作为HFpEF的启动剂和HFrEF的恶化剂,需要不同的治疗策略.
- 向丁信号传递需要研究,特别是在心脏代谢的HFpEF.
- 解决代谢和心血管方面的综合治疗是改善所有HF患者治疗结果的关键.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545